Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Frontiers in Pharmacology|April 9, 2015
7α, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseasesSiquan Sun, Changlu LiuExpert Opinion on Therapeutic Patents|February 24, 2011
Cathepsin S inhibitors: 2004-2010Alice Lee-Dutra, Danielle K Wiener, Siquan SunCurrent Topics in Medicinal Chemistry|March 27, 2010
Recent advances in the design of cathepsin S inhibitorsJohn J M Wiener, Siquan Sun, Robin L ThurmondCurrent Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
Cathepsin S inhibitors as novel immunomodulatorsRobin L Thurmond, Siquan Sun, Lars Karlsson, et al.Inflammation & Allergy Drug Targets|January 29, 2008
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disordersSiquan Sun, Navin L Rao, Jennifer Venable, et al.Bioorganic & Medicinal Chemistry Letters|September 24, 2016
Fluoro analogs of bioactive oxy-sterols: Synthesis of an EBI2 agonist with enhanced metabolic stabilityXiaohu Deng, Siquan Sun, Jiejun Wu, et al.Plos One|February 21, 2020
The PAR2 signal peptide prevents premature receptor cleavage and activationBelinda Liu, Grace Lee, Jiejun Wu, et al.Bioorganic & Medicinal Chemistry Letters|January 15, 2013
Pyrazole-based arylalkyne cathepsin S inhibitors. Part III: modification of P4 regionJohn J M Wiener, Alvah Tyson Wickboldt, Steven Nguyen, et al.The Journal of Cell Biology|March 29, 2006
CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretionMiguel A Sanjuan, Navin Rao, Kuei-Tai A Lai, et al.Journal of Medicinal Chemistry|September 17, 2004
Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin SRobin L Thurmond, Mary Pat Beavers, Hui Cai, et al.Pageof 3